Clinical experience with Certican® (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin

Journal of Heart and Lung Transplantation

Volumn 24, Issue 4 SUPPL., 2005, Pages

  Lehmkuhl, Hans ^a   Hetzer, Roland ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN A; EVEROLIMUS; FLUINDOSTATIN; LIPID; STEROID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; EXPERIENCE; FEMALE; GERMANY; HEALTH CENTER; HEART TRANSPLANTATION; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL PATIENT;

EID: 15044351065     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2005.01.011     Document Type: Article

References (20)

1. D. Marelli, H. Laks, J.A. Kobashigawa Seventeen-year experience with 1,083 heart transplants at a single institution Ann Thorac Surg 74 2002 1558 1566
2. F.C. Tsai, D. Marelli, J. Bresson Recent trends in early outcome of adult patients after heart transplantation a single-institution review of 251 transplants using standard donor organs Am J Transplant 2 2002 539 545
3. J.M. Smits, J. De Meester, M.C. Deng Mortality rates after heart transplantation how to compare center-specific outcome data Transplantation 15 2003 90 96
4. D.F. Del Rizzo, A.H. Menkis, P.W. Pflugfelder The role of donor age and ischemic time on survival following orthotopic heart transplantation J Heart Lung Transplant 18 1999 310 319
5. J. Kobashigawa What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med 1 2000 166 171
6. L.D. Sharples, C.H. Jackson, J. Parameshwar, J. Wallwork, S.R. Large Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy Transplantation 27 2003 679 682
7. W.M. Bennett Insights into chronic cyclosporine nephrotoxicity Int J Clin Pharmacol Ther 34 1996 515 519
8. V. Sakhuja, U.K. Sharma, V. Jha, M. Minz, K.S. Chugh High incidence of posttransplant diabetes mellitus in renal transplant recipients on triple-drug immunosuppression Transplant Proc 27 1995 2728 2730
9. J. Kobashigawa, L. Miller, R. Dale A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients Transplantation 66 1998 507 515
10. H.J. Eisen, E.M. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients N Engl J Med 349 2003 847 858
11. A. Keogh, M. Richardson, P. Ruygrok Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease Circulation 110 2004 10 16
12. Haverich A, Tuzcu EM, Vigano M, et al. Everolimus in de novo cardiac transplant recipients: 24-month follow-up. Abstract presented at the annual meeting and scientific sessions of the 23rd International Society for Heart and Lung Transplantation, April 9-12, 2003, Vienna, Austria.
13. E.M. Tuzcu, J.A. Kobashigawa, H.J. Eisen Favorable effect of everolimus on cardiac allograft vasculopathy is maintained through 24 months 2004 American Transplant Congress (Abstract 1547)
14. H.J. Schuurman, S. Cottens, S. Fuchs SDZ, a new rapamycin derivative synergism with cyclosporine Transplantation 64 1997 32 35
15. B. Nashan, J. Curtis, C. Ponticelli 156 Study Group Everolimus and reduced-exposure cyclosporine in de novo renal transplant recipients a three-year, Phase II, randomized, multicenter, open-label study Transplantation 78 2004 1332 1340
16. S. Vitko, H. Tedesco, J. Eris Everolimus with optimized cyclosporine dosing in renal transplant recipients 6-month safety and efficacy results of two randomized studies Am J Transplant 4 2004 626 635
17. R.C. Starling, J.M. Hare, P. Hauptman Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling Am J Transplantation 4 2004 2126 2131
18. M.R. Mehra, N.Y. Raval Meta-analysis of statins and survival in de novo cardiac transplantation Transplant Proc 36 2004 1539 1541
19. Kobashigawa J. Further analysis of the intravascular ultrasound (IVUS) data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipients. Data presented at the 24th annual meeting of the International Society for Heart and Lung Transplantation, San Francisco, CA, April 2004.
20. K. Pethig, B. Heublein, T. Wahlers Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy influence on inflammation and progression of intimal hyperplasia J Heart Lung Transplant 23 2004 61 66